<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008679</url>
  </required_header>
  <id_info>
    <org_study_id>TJ-HF-NI</org_study_id>
    <nct_id>NCT05008679</nct_id>
  </id_info>
  <brief_title>The Effects of Neuraminidase Inhibitor Oseltamivir in Patients With Chronic Heart Failure</brief_title>
  <official_title>The Effects of Neuraminidase Inhibitor Oseltamivir in Patients With Chronic Heart Failure: an Open Label, Randomized, Blank-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure (HF) is a complex syndrome with increasing incidence and high rates of&#xD;
      mortality and hospitalization. Although inhibitors of angiotensin converting enzyme (ACE),&#xD;
      Î²-blockers and aldosterone-receptor blockers have improved the treatment of heart failure,&#xD;
      mortality of HF remains unacceptably high.&#xD;
&#xD;
      Recently, we identified a key metabolite N-acetylneuraminic acid (Neu5Ac) increased in the&#xD;
      plasma of patients with heart failure. Also, elevated plasma Neu5Ac, independent of other&#xD;
      traditional risk factors, is associated with poor prognosis in patients with HF in long-term&#xD;
      follow up. Neu5Ac levels, the most common sialic acid in mammals, generated from sialylated&#xD;
      glycoconjugates by neuraminidase. Neu5Ac and its regulatory enzyme neuraminidase play a key&#xD;
      role in heart failure. We found neuraminidase inhibitor could reduce Neu5Ac levels and&#xD;
      improve heart failure in mice model, providing opportunity for a novel therapeutic strategy&#xD;
      in HF. Neuraminidase inhibitor oseltamivir is also an old anti-influenza drug. Using&#xD;
      oseltamivir may be a new therapeutic strategy in heart failure.&#xD;
&#xD;
      Based on above information, we designed the randomized, open-label, blank-controlled study in&#xD;
      patients with chronic HF to receive either oseltamivir or placebo, in addition to standard HF&#xD;
      therapy to Identify the effect of oseltamivir on serum Neu5Ac level in patients with heart&#xD;
      failure and assess the clinic outcomes of level in patients with heart failure using&#xD;
      oseltamivir.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">January 25, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>1 month</time_frame>
    <description>Reduction of NT-proBNP level at 1 month treatment of Oseltamivir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EF (ejection fraction)</measure>
    <time_frame>1month, 6 months</time_frame>
    <description>Cardiac systolic function assessed by ejection fraction using echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Classification</measure>
    <time_frame>1month, 6 months</time_frame>
    <description>NYHA Classification after treatment of Oseltamivir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>1month, 6 months</time_frame>
    <description>Minnesota Heart Failure Quality of life assessment after treatment of Oseltamivir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test</measure>
    <time_frame>1month, 6 months</time_frame>
    <description>6-minute walk test after treatment of Oseltamivir</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">388</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients with heart failure to receive standard HF therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with heart failure to receive oseltamivir (at a dose of 75 mg twice daily) for 1 month in addition to standard HF therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>at a dose of 75 mg twice daily</description>
    <arm_group_label>Oseltamivir</arm_group_label>
    <other_name>Neuraminidase Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 of age or older, regardless of gender;&#xD;
&#xD;
          2. Patients with NYHA II-IV, LVEF less than 40%;&#xD;
&#xD;
          3. Levels of NT-proBNP more than 450 pg/ml&#xD;
&#xD;
          4. Willing to participate in this study and sign an informed consent, and receive&#xD;
             follow-up contact for at least 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Onset of acute myocardial infarction within the last 1 month;&#xD;
&#xD;
          2. Had cardiac surgery or onset of cerebrovascular accident within the last 6 months;&#xD;
&#xD;
          3. Plan to have cardiac transplantation or CRT, or already having CRT therapy;&#xD;
&#xD;
          4. Females with pregnancy or plan to have pregnancy;&#xD;
&#xD;
          5. Have participate in any other clinical trial within the last 3 months;&#xD;
&#xD;
          6. Severe neurological disorders (Alzheimer's disease, progressive stage of Parkinson's&#xD;
             syndrome), disabilities of lower limbs or deaf-mute;&#xD;
&#xD;
          7. had a history of tumour, or precancerous lesions confirmed by pathological tests&#xD;
             (ductal carcinoma in situ, cervical dysplasia, etc.);&#xD;
&#xD;
          8. had malignant tumours (by physical examinations, X-ray, type-B ultrasonic imaging or&#xD;
             other methods), or had hyperplastic glands or adenoma which possess endocrine activity&#xD;
             and affect cardiac or endocrine functions (pheochromocytoma, goitre, etc.);&#xD;
&#xD;
          9. The subjects who refuse to comply with the items of the research protocol;&#xD;
&#xD;
         10. The subjects who are not available to fulfil the follow-up plan (due to project&#xD;
             management or other reasons), according to the judgement of researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dao Wen Wang, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Ni, Phd</last_name>
    <phone>862783662479</phone>
    <email>nili@tjh.tjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Ni, PHD</last_name>
      <phone>+862783662479</phone>
      <email>nili@tjh.tjmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 14, 2021</study_first_submitted>
  <study_first_submitted_qc>August 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 14, 2021</last_update_submitted>
  <last_update_submitted_qc>August 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Dao Wen Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>Neuraminidase inhibitor</keyword>
  <keyword>oseltamivir</keyword>
  <keyword>Neu5Ac</keyword>
  <keyword>NTproBNP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

